Literature DB >> 15924253

PIK3CA mutations in glioblastoma multiforme.

Christian Hartmann1, Gesine Bartels, Claire Gehlhaar, Nikola Holtkamp, Andreas von Deimling.   

Abstract

Glioblastoma multiforme WHO grade IV is the most common and malignant variant of astrocytic tumors. Loss of heterozygosity of chromosome 10 and mutations in the tumor suppressor gene PTEN on 10q are molecular hallmarks of glioblastomas. Recently, mutations were identified in PIK3CA, encoding a protein that antagonizes the function of PTEN protein in the PI3K/Akt pathway. To address the question whether an exclusive mutation pattern can be observed in PIK3CA and PTEN, we determined the frequency of mutations in both genes. All coding exons were examined by single strand confirmation polymorphism and direct sequencing. Additionally, we analyzed chromosome 10 for loss of heterozygosity and evaluated the mutational status of TP53. In 70 glioblastomas, 5 (7%) PIK3CA mutations and 10 (14%) PTEN mutations were found. All mutations in PIK3CA located to exons 1, 9 and 20, thereby supporting the concept of mutational hot spot regions. In all but one glioblastoma, mutations were seen either in PIK3CA or in PTEN. In conclusion, the frequency of PIK3CA mutations in glioblastomas appears to be much lower than initially reported.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15924253     DOI: 10.1007/s00401-005-1000-1

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  37 in total

Review 1.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

2.  Spatiotemporal genomic architecture informs precision oncology in glioblastoma.

Authors:  Jin-Ku Lee; Jiguang Wang; Jason K Sa; Erik Ladewig; Hae-Ock Lee; In-Hee Lee; Hyun Ju Kang; Daniel S Rosenbloom; Pablo G Camara; Zhaoqi Liu; Patrick van Nieuwenhuizen; Sang Won Jung; Seung Won Choi; Junhyung Kim; Andrew Chen; Kyu-Tae Kim; Sang Shin; Yun Jee Seo; Jin-Mi Oh; Yong Jae Shin; Chul-Kee Park; Doo-Sik Kong; Ho Jun Seol; Andrew Blumberg; Jung-Il Lee; Antonio Iavarone; Woong-Yang Park; Raul Rabadan; Do-Hyun Nam
Journal:  Nat Genet       Date:  2017-03-06       Impact factor: 38.330

3.  Cancer-specific mutations in PIK3CA are oncogenic in vivo.

Authors:  Andreas G Bader; Sohye Kang; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

Review 4.  Will kinase inhibitors make it as glioblastoma drugs?

Authors:  Ingo K Mellinghoff; Nikolaus Schultz; Paul S Mischel; Timothy F Cloughesy
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 5.  Class I PI3K in oncogenic cellular transformation.

Authors:  L Zhao; P K Vogt
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

Review 6.  Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.

Authors:  Yujun Hao; Shuliang Zhao; Zhenghe Wang
Journal:  Toxicol Pathol       Date:  2013-10-31       Impact factor: 1.902

Review 7.  The PIK3CA gene as a mutated target for cancer therapy.

Authors:  John P Gustin; David P Cosgrove; Ben Ho Park
Journal:  Curr Cancer Drug Targets       Date:  2008-12       Impact factor: 3.428

Review 8.  PI3K signaling in glioma--animal models and therapeutic challenges.

Authors:  Christine K Cheng; Qi-Wen Fan; William A Weiss
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

9.  Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.

Authors:  Alberto Broniscer; Suzanne J Baker; Clinton F Stewart; Thomas E Merchant; Fred H Laningham; Paula Schaiquevich; Mehmet Kocak; E Brannon Morris; Raelene Endersby; David W Ellison; Amar Gajjar
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

10.  Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.

Authors:  Bijay S Jaiswal; Vasantharajan Janakiraman; Noelyn M Kljavin; Subhra Chaudhuri; Howard M Stern; Weiru Wang; Zhengyan Kan; Hashem A Dbouk; Brock A Peters; Paul Waring; Trisha Dela Vega; Denise M Kenski; Krista K Bowman; Maria Lorenzo; Hong Li; Jiansheng Wu; Zora Modrusan; Jeremy Stinson; Michael Eby; Peng Yue; Josh S Kaminker; Frederic J de Sauvage; Jonathan M Backer; Somasekar Seshagiri
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.